Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Market-moving news hits ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.

We like it.” Eli Lilly (NYSE:LLY) develops and markets a broad range of pharmaceuticals for conditions such as diabetes, obesity, cancer, autoimmune diseases, and neurological disorders.

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Eli Lilly (LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (VERV) for up to $1.3 billion, the Financial Times reported.